Summary
Karim Ghoufiri
Business developper
Technology
- IL-1 or Interleukin-1 is a pro-inflammatory cytokin, primarily comprising two forms : IL-1α and IL-1β. IL-1 is a promising target for developing therapies to rebalance immune responses and improve allergy treatment.
- IL-1 regulates the allergic response in two ways :
- Shifts the immune response toward an IgG response
- Up-regulates FcyRIIb inhibitory receptors on mast cells, lowering their reactivity when exposed to allergens
Market
- Limitations of conventional allergen immunotherapy : long treatment duration, inconsistent efficacy, adverse reactions
- Market size : ~ $31.6 billion globally; ~32% of the population suffering from allergy
Development
- In vivo proof of concept
- Ongoing studies on various allergy models
IP
- A PCT patent application published under No. WO2024/175548, with a priority filing date of 2023/02/20. The application has entered the national phase in AU, CA, EU, US, JP.
Valorisation strategy
- Licensing